Washington, D.C. (January 31, 2023) – The Biosimilars Council released the following statement in response to the new IQVIA report, Biosimilars in the United States 2023-2027.
“Today’s IQVIA report comes at the same time as launch of the first of at least 8 lower priced biosimilar versions of Humira. Together, they highlight the opportunity to reduce patient spending through more affordable biosimilars as well as the need to address perverse market incentives under which PBMs prefer higher-priced medicines” said Craig Burton, Executive Director of the Biosimilars Council. “The report highlights the resiliency of the biosimilars market and proves once more that patient access to biosimilar medicines expands access and yields remarkable savings. To maximize savings through biosimilar adoption, policymakers should take swift action to eliminate these barriers and expand patient access to lower-priced biosimilars.”